ARVINAS New Haven, Connecticut
To treat cancers and other difficult diseases, Arvinas is developing a new class of drugs called PROTACs (proteolysis-targeting chimeras). They engage the body’s natural protein disposal system, the ubiquitin/proteasome system, which routinely removes damaged proteins. PROTACs degrade disease-causing proteins and then are released to continue their seek-and-destroy mission.
Craig Crews, Yale University Professor of Molecular, Cellular and Developmental Biology, founded Arvinas in 2012, using technology licensed from Yale.
- An infusion of $112M through Series A & B
- $15.3M Series A investment round
- $41.6M Series B investment round
- $55M Series C investment round
- Connecticut Innovations, *DECD and private venture capital
firms all participated
- CI has invested $3,893,791 to date
- *DECD has provided a $2.5M loan for R&D/employee growth
- $3.25M in loan financing
- In 2013 Nature Biotechnology named Arvinas a Top Spinout.
- FierceBiotech names Arvinas as one of its “Fierce 15” Biotech Companies of 2015
- Arvinas has added 45 new employees through May 2017 and expects to add more in the future, including researchers and management, taking advantage of CTNext, the state’s innovation ecosystem, to acquire new talent.
- Arvinas is working on multiple programs targeting several types of cancers, including prostate cancer and breast cancer. It continues to work closely with Yale University scientists.
- The firm has forged two strategic R&D collaborations with Merck and Genentech and is exploring other diverse partnering opportunities.
- September 26, 2018: Raised $120M IPO Nasdaq: ARVN